PD-1 inhibitors are widely utilized in cancer therapy, but the main challenges in developing successful drugs for immune checkpoint blockade are the selection of patient subgroups that would benefit most from these agents and the avoidance of ineffective treatments and potential side effects related to autoimmune effects resulting from blocking the PD-1/PD-L1 pathway [25, 26]. The gene discussed is CD274; the disease is cancer.